FDA Approves Droplet Micron For OTC Sale And Expanded Medical Use

The US Food & Drug Administration has recently broadened the scope of use for the Droplet Micron 34G x 3.5mm pen needle, a product of HTL-Strefa, part of the MTD Group. This significant regulatory update not only extends the needle's application beyond insulin injections but also transitions its availability from prescription-only to over-the-counter (OTC) in the United States. This move is set to enhance patient care by facilitating easier access to what is currently the thinnest and shortest pen needle available in the country.

The Droplet Micron pen needle now carries an indication for the "subcutaneous injection of drugs," a development that allows its use with a wider range of medications, including GLP-1s. This expansion aims to diversify treatment options for patients and improve accessibility. In tandem with this broader indication, the needle will no longer bear the "Rx Only" label in the US, simplifying its distribution through pharmacies and online platforms, subject to state and provincial regulations. Consumers can find Droplet Micron OTC on Amazon, where state laws permit, and it is expected to hit shelves in numerous national retailers soon.

Droplet Micron stands out for its patient-centric design, which significantly reduces penetration force by up to 50%, potentially offering a less painful injection experience. This innovation has earned it high ratings from users worldwide, reinforcing its position as a leading choice for safe, reliable, and comfortable injections. For more information or to request samples, interested parties are encouraged to visit www.mydroplet.com.

About HTL-Strefa and MTD Group

HTL-Strefa operates under the umbrella of Medical Technology and Devices (MTD) Group, a conglomerate established in 2018 through the merger of Pikdare and HTL-Strefa. MTD Group has emerged as a powerhouse in the med-tech sector, specializing in the design, development, and global distribution of an extensive array of medical devices suited for both home and professional use. Annually, the group supplies around 5 billion medical devices worldwide, underpinned by a robust commitment to research and development. Presently involved in over 100 R&D projects and holding more than 300 patents, MTD's innovation drive is evident.

In 2020, MTD further solidified its commitment to innovation by establishing MTD Engineering, a technological hub dedicated to fostering new projects for its product pipeline. With a presence in over 100 countries, either directly or through subsidiaries, and boasting four state-of-the-art production facilities in Europe, MTD Group is a global leader in medical technology. The group is majority-owned by Investindustrial with QuattroR SGR also holding a stake. Employing approximately 1,700 individuals, MTD Group reported a turnover of about 250 million euros in 2022.